

Agenus to File an IND for its PhosphoSynVax™ (PSV™) Cancer Vaccine


PSV represents an Application of Agenus' Proprietary Phosphopeptide Tumor Targets (PTTs)

What are PTTs?

- PTTs are small protein fragments unique to cancers that arise from dysregulated protein processing in cancer cells.
- It is believed that the immune system can recognize PTTs as foreign and kill cancer cells that express them. Hence, PTTs have the potential to be universal neo-antigen targets and are ideal candidates for the development of off-the-shelf cancer vaccines and cell therapy.

What are Agenus' Proprietary Phosphopeptide Tumor Targets (PTTs) and how are we using them?

- We have developed **unique and proprietary methods of identifying the right PTTs**, specific for a tumor type.
- Agenus has amassed a library of more than **2000 phosphorylated peptides** and **we have identified ~50 PTTs shared among cancer patients and across multiple tumor types**.
- **Agenus is pursuing both off-the-shelf cancer vaccines and cell therapy with our proprietary position in PTT targets**.
 - In addition to our TCR discovery programs, we are using these PTTs for developing multiple vaccines that use our proprietary QS-21 Stimulon™ adjuvant and our HSP delivery system, making our vaccine platform and cancer vaccine targets unique in the cancer vaccine field.



PhosphoSynVax™ (PSV™): Agenus' Universal Neoantigen Cancer Vaccine Platform

PSV™ is Agenus' neoantigen vaccine platform for targeting cancer-specific PTTs shared amongst identifiable groups of cancer patients. Our PSV vaccine is designed to train the patient's immune system to recognize and kill tumor cells and promote lasting anti-tumor immunity for improved survival. Our PSV vaccines incorporate multiple PTTs and, in combination with our novel checkpoint antibodies, are designed to stimulate a broad anti-tumor immune response and address tumor escape mechanisms to prevent relapse. PSV is a universal cancer vaccine platform designed for optimal efficacy whilst offering operational and cost advantages relative to individualized neoantigen vaccine approaches.

PSV™-AML: A Vaccine for Acute Myeloid Leukemia (AML)

Why AML?

- Standard-of-care in AML has remained relatively unchanged: 5-year mortality rate remains over 75%
- Response to current standard of care chemotherapy: Transient, many patients relapse within one year
- There are no currently approved immunotherapies for AML

What is Agenus' PSV-AML?

The Agenus PSV™ vaccine for AML was created by genetic sequencing of numerous AML patient samples. Using our proprietary algorithms, we selected 30 PTTs for our PSV vaccine for AML. Based on our profiling of AML patient populations, we expect that our PSV vaccine, if approved, can be used to treat approximately **70% of the US AML population**¹. Furthermore, 95% of eligible AML patients are expected to present at least one PTT included in our vaccine.

What are the key differentiating features of PSV-AML?

- Off the shelf vaccine: Readily available, with considerable manufacturing and operational advantages compared to individualized formulations
 - Incorporates multiple PTTs, contrary to current "single antigen" approaches, which target only a limited patient population and compromise on the robustness of immune response
 - Mutational neoantigens allow for one vaccine which treats one patient. PTTs allow for an off-the-shelf vaccine which treats many patients
- We believe that Agenus is the only company currently focused on the identification of PTTs and their incorporation into immunotherapies

We are on track to file an IND for PSV-AML in the coming weeks. We plan to generate safety and immunogenicity data in healthy volunteers first. Following this, we plan to evaluate PSV™-AML as a maintenance therapy for high-risk AML patients in complete remission after induction and consolidation chemotherapy. Further treatment settings such as second-line therapy for patients with refractory or relapsed disease may also be explored.

¹Agenus proprietary analysis